Patents by Inventor Sami Hashim

Sami Hashim has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Glyceryl tris (beta-hydroxybutyrate) and neuronal transient ischemic attacks
    Patent number: 12239624
    Abstract: A method of use of Glyceryl Tris (Beta-hydroxybutyrate) in the minimization, reduction, or prevention of neuronal deficit and/or neuronal cell death with respect to follow-on neuronal transient ischemic attacks (NTIAs) in subjects who have had (or in subjects exhibiting symptomology of having had) at least one prior NTIA.
    Type: Grant
    Filed: May 30, 2019
    Date of Patent: March 4, 2025
    Assignee: NeuroEnergy Ventures, Inc.
    Inventor: Sami Hashim
  • Glyceryl 3-hydroxybutyrates for traumatic brain injury
    Patent number: 11638702
    Abstract: A method of treatment of mild to moderate non-penetrating closed traumatic brain injury and mild to moderate TBI due to surgical intervention using 3-hydroxybutyate glycerides is disclosed.
    Type: Grant
    Filed: June 10, 2020
    Date of Patent: May 2, 2023
    Assignee: NeuroEnerygy Ventures, Inc.
    Inventor: Sami Hashim
  • GLYCERYL TRIS (BETA-HYDROXYBUTYRATE) AND NEURONAL TRANSIENT ISCHEMIC ATTACKS
    Publication number: 20220288006
    Abstract: A method of use of Gylceryl Tris (Beta-hydroxybutyrate) in the minimization, reduction, or prevention of neuronal deficit and/or neuronal cell death with respect to follow-on neuronal transient ischemic attacks (NTIAs) in subjects who have had (or in subjects exhibiting symptomology of having had) at least one prior NTIA.
    Type: Application
    Filed: May 30, 2019
    Publication date: September 15, 2022
    Applicant: NeuroEnergy Ventures, Inc.
    Inventor: SAMI HASHIM
  • Glyceryl 3-hydroxybutyrates for migraine symptom management
    Patent number: 10792269
    Abstract: A method of management of migraine symptom reduction and/or management and/or prophylaxis is disclosed using 3-hydroxybutyrate glycerides is disclosed.
    Type: Grant
    Filed: December 14, 2018
    Date of Patent: October 6, 2020
    Assignee: NeuroEnergy Ventures, Inc.
    Inventor: Sami Hashim
  • GLYCERYL 3-HYDROXYBUTYRATES FOR TRAUMATIC BRAIN INJURY
    Publication number: 20200297686
    Abstract: A method of treatment of mild to moderate non-penetrating closed traumatic brain injury and mild to moderate TBI due to surgical intervention using 3-hydroxybutyate glycerides is disclosed.
    Type: Application
    Filed: June 10, 2020
    Publication date: September 24, 2020
    Applicant: NeuroEnerygy Ventures, Inc.
    Inventor: Sami Hashim
  • Glyceryl 3-hydroxybutyrates for traumatic brain injury
    Patent number: 10736867
    Abstract: A method of treatment of mild to moderate non-penetrating closed traumatic brain injury and mild to moderate TBI due to surgical intervention using 3-hydroxybutyate glycerides is disclosed.
    Type: Grant
    Filed: March 1, 2018
    Date of Patent: August 11, 2020
    Assignee: Neuroenergy Ventures, Inc.
    Inventor: Sami Hashim
  • GLYCERYL 3-HYDROXYBUTYRATES FOR MIGRAINE SYMPTOM MANAGEMENT
    Publication number: 20190117612
    Abstract: A method of management of migraine symptom reduction and/or management and/or prophylaxis is disclosed using 3-hydroxybutyrate glycerides is disclosed.
    Type: Application
    Filed: December 14, 2018
    Publication date: April 25, 2019
    Applicant: NeuroEnergy Ventures, Inc.
    Inventor: Sami Hashim
  • GLYCERYL 3-HYDROXYBUTYRATES FOR TRAUMATIC BRAIN INJURY
    Publication number: 20180193300
    Abstract: A method of treatment of mild to moderate non-penetrating closed traumatic brain injury and mild to moderate TBI due to surgical intervention using 3-hydroxybutyate glycerides is disclosed.
    Type: Application
    Filed: March 1, 2018
    Publication date: July 12, 2018
    Applicant: NeuroEnergy Ventures, Inc.
    Inventor: Sami Hashim
  • GLYCERYL 3-HYDROXYBUTYRATES FOR MIGRAINE SYMPTOM MANAGEMENT
    Publication number: 20180177753
    Abstract: A method of management of migraine symptom reduction and/or management and/or prophylaxis is disclosed using 3-hydroxybutyate glycerides is disclosed.
    Type: Application
    Filed: December 23, 2016
    Publication date: June 28, 2018
    Applicant: NeuroEnergy Ventures, Inc.
    Inventor: Sami Hashim
  • Glyceryl 3-hydroxybutyrates for traumatic brain injury
    Patent number: 9925164
    Abstract: A method of treatment of mild to moderate non-penetrating closed traumatic brain injury and mild to moderate TBI due to surgical intervention using 3-hydroxybutyate glycerides is disclosed.
    Type: Grant
    Filed: January 12, 2017
    Date of Patent: March 27, 2018
    Assignee: NeuroEnergy Ventures, Inc.
    Inventor: Sami Hashim
  • Glyceride esters for the treatment of diseases associated with reduced neuronal metabolism of glucose
    Patent number: 7807718
    Abstract: Provided are alternative sources of ketone bodies for reducing or eliminating symptoms of Parkinson's disease, amyotrophic lateral sclerosis (ALS, also called Lou Gehrig's disease), Alzheimer's disease, Huntington's disease, epilepsy and other diseases or disorders characterized by impaired glucose metabolism. The alternative sources of ketone bodies include mono-, di- and triglyceride esters of acetoacetate and mixtures thereof, and/or mono-, di- and triglyceride esters of 3-hydroxybutyrate and mixtures thereof. These glyceride esters can be administered orally as a dietary supplement or in a nutritional composition.
    Type: Grant
    Filed: June 29, 2007
    Date of Patent: October 5, 2010
    Inventors: Sami A. Hashim, Joanna Jusis, Jenifer Heydinger Galante, Joseph C. Rongione
  • Glyceride Esters for the Treatment of Diseases Associated with Reduced Neuronal Metabolism of Glucose
    Publication number: 20090197952
    Abstract: Provided are alternative sources of ketone bodies for reducing or eliminating symptoms of Parkinson's disease, amyotrophic lateral sclerosis (ALS, also called Lou Gehrig's disease), Alzheimer's disease, Huntington's disease, epilepsy and other diseases or disorders characterized by impaired glucose metabolism. The alternative sources of ketone bodies include mono-, di- and triglyceride esters of acetoacetate and mixtures thereof, and/or mono-, di- and triglyceride esters of 3-hydroxybutyrate and mixtures thereof. These glyceride esters can be administered orally as a dietary supplement or in a nutritional composition.
    Type: Application
    Filed: June 29, 2007
    Publication date: August 6, 2009
    Inventors: Sami A. Hashim, Joanna Jusis, Jenifer Heydinger Galante, Joseph C. Rongione